Data as of 4:03pm ET
| +0.01 / +0.28%|
BioTime, Inc. is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. The company develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary ReCyte Therapeutics, Inc. It also plans to develop therapeutic products in China for the treatment of ophthalmologic, skin, musculo-skeletal system and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer through its subsidiary BioTime Asia Ltd. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic surgery and technology for use in surgery, emergency trauma treatment and other applications. Its focus is in the field of regenerative medicine; specifically human embryonic stem cell and induced pluripotent stem cell technology. BioTime was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
|Michael D. West||President, Chief Executive Officer & Director|
|Robert W. Peabody||Senior VP, Chief Operating & Financial Officer|
|Hal Sternberg||Vice President-Research|
|Judith Segall||Secretary, Director & VP-Administration|
|William P. Tew||Chief Commercial Officer|